A Synthetic ERR Agonist Alleviates Metabolic Syndrome

This study by the Burris team and collaborators investigated the metabolic effects of SLU-PP-332, an agonist of estrogen-related receptors (ERR), in murine models of metabolic syndrome induced by a high-fat diet. The work represented an extension of the 2023 findings, now focusing on the systemic metabolic consequences of pharmacological ERR activation.

Mice treated with SLU-PP-332 showed a significant increase in energy expenditure and fatty acid oxidation, mimicking the metabolic benefits of regular physical exercise. There was effective reduction in body weight and adiposity, with marked improvement in the overall metabolic profile.

• Insulin sensitivity improved significantly in treated animals
• Reductions in serum triglyceride and cholesterol levels were observed
• The compound demonstrated anti-obesity effects even without changes in food intake
• Inflammation markers associated with metabolic syndrome were attenuated

The results reinforced the therapeutic potential of pharmacological ERR modulation as a strategy for treating metabolic syndrome, particularly in patients unable to perform physical exercise. The study, published in the Journal of Pharmacology and Experimental Therapeutics, expanded the understanding of SLU-PP-332's systemic effects, positioning the ERR pathway as a promising target for developing new anti-obesity drugs.